Hongnan Mo

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Yuanyuan Zhang, Hongyan Chen, Hongnan Mo et al. · Cancer Cell · 2021 · 730 citations · Full text

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

Jing Huang, Binghe Xu, Hongnan Mo et al. · Clinical Cancer Research · 2018 · 216 citations

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Hongnan Mo, Jing Huang, Jiachen Xu et al. · British Journal of Cancer · 2018 · 156 citations · Full text

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China

Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo et al. · Frontiers in Oncology · 2022 · 118 citations · Full text

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Pin Zhang, Yi Yin, Hongnan Mo et al. · Oncotarget · 2016 · 95 citations · Full text